Is There Clinical Value to Prognostic Signatures in Early-Stage NSCLC?

被引：4

作者：

Bunn, Paul A., Jr. ^{[1
]}

Hirsch, Fred R. ^{[1
,2
]}

Aisner, Dara L. ^{[2
]}

机构：

[1] Univ Colorado Denver, Univ Colorado Canc Ctr, Dept Med, Div Med Oncol, Aurora, CO 80045 USA

[2] Univ Colorado Denver, Univ Colorado Canc Ctr, Dept Pathol, Aurora, CO 80045 USA

来源：

CLINICAL CANCER RESEARCH | 2014年 / 20卷 / 07期

关键词：

CELL LUNG-CANCER; ADJUVANT CHEMOTHERAPY; PREDICT SURVIVAL; VALIDATION; ASSAY; RISK;

D O I：

10.1158/1078-0432.CCR-13-3387

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

pAMPK and pmTOR favorably predicted outcome in early non-small cell lung cancer (NSCLC). The differences were small. Phosphoprotein lability makes routine clinical use and validation difficult. Protein immunohistochemistry is unlikely to be clinically useful, and numerous efforts to create predictive models to select resected patients for therapy have been unsuccessful. (C) 2014 AACR.

引用

页码：1727 / 1729

页数：3

共 50 条

[1] Prognostic value of "angiogenic" risk score in early-stage NSCLC.
Sanmartin, Elena
Jantus-Lewintre, Eloisa
Sirera, Rafael
Javier Sanchez, Jose
Uso, Marta
Gallach, Sandra
Blasco, Ana
Hernando, Cristina
Martinez, Nieves
Figueroa, Santiago
Diego Rolfo, Christian
Guijarro, Ricardo
Martorell, Miguel
Camps, Carlos
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[2] Prognostic value of FDG uptake in early stage NSCLC
Lee Shih-Chun
Chen Jen-Chih
Chang Hung
Cheng Yeung-Leung
Ching Tzao
Huang Wen-Shen
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S738 - S739
[3] Surgery of Early-Stage NSCLC
Mueller, Michael
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S40 - S42
[4] Transcriptomic Signatures in Elderly Patients With Early-stage NSCLC Are Associated With Disease Recurrence
Darawshy, F.
Tsay, J. J.
Sulaiman, I.
Kwok, B.
Wong, K.
Li, Y.
Schluger, R.
Chang, M.
Li, Q.
Sterman, D. H.
Tsirigos, A.
Pass, H.
Segal, L. N.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
[5] Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC br
Jung, Hyun Ae
Lim, Jinyeong
Choi, Yoon-La
Lee, Se-Hoon
Joung, Je-Gun
Jeon, Yeong Jeong
Choi, Jae Won
Shin, Sumin
Cho, Jong Ho
Kim, Hong Kwan
Choi, Yong Soo
Zo, Jae Ill
Shim, Young Mog
Park, Sehhoon
Sun, Jong-Mu
Ahn, Jin Seok
Ahn, Myung-Ju
Han, Joungho
Park, Woong-Yang
Kim, Jhingook
Park, Keunchil
CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4312 - 4321
[6] Multiomic plasma profiling identifies potential signatures of disease progression in early-stage NSCLC
Vallania, Francesco
Warsinske, Hayley
Ulz, Peter
Liu, Tzu-Yu
Assayag, Karen
Palaniappan, Krishnan K.
Bailey, Mitch
Wang, Irving
Weinberg, David E.
Ennis, Riley
Lin, C. Jimmy
Martin, Anne-Marie
Krunic, Nancy
CANCER RESEARCH, 2020, 80 (16)
[7] Expression of Treg Associated Markers Have Prognostic Implications in Early-stage NSCLC
Jantus-Leintre, E.
Uso, M.
Gallach, S.
Sanmartin, E.
Blasco, A.
Guijarro, R.
Ortiz, C.
Martorell, M.
Sirera, R.
Camps, C.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S123 - S123
[8] The Role of Lymphadenectomy in Early-Stage NSCLC
Manfredini, Beatrice
Zirafa, Carmelina Cristina
Filosso, Pier Luigi
Stefani, Alessandro
Romano, Gaetano
Davini, Federico
Melfi, Franca
CANCERS, 2023, 15 (14)
[9] MOLECULAR EXPRESSION OF ANGIOGENIC MARKERS IN EARLY-STAGE NSCLC: EVALUATION OF THE PROGNOSTIC ROLE
Jantus, E.
Cabrera, A.
Sirera, R.
Uso, M.
Gallach, S.
Blasco, A.
Berrocal, A.
Taron, M.
Rosell, R.
Camps, C.
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S67 - S67
[10] Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study
Cho, Byoung Chul
De Pas, Tommaso
Kalofonos, Haralabos
Wang, Qun
Ramlaus, Rodryg
Cheng, Ying
Vitiello, Fabiana
Laisaar, Tanel
Vallieres, Eric
Kubisa, Bartosz
Orlov, Sergey
Park, Keunchil
Debruyne, Channa
Vansteenkiste, Johan
ANTICANCER RESEARCH, 2019, 39 (03) : 1403 - 1409

← 1 2 3 4 5 →